Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ANTX
AN2 THERAPEUTICS, INC.
NASDAQ
$5.58
▼ DOWN 2.79% (-0.16)

KEY STATISTICS

Market Cap$200.97 M
52w High$7.19
52w Low$1.00
Dividend Yield17.05%
FrequencyQuarterly
P/E-5.07
Volume240.87K
Shares Out.36.02M

COMPANY

LEADERSHIP

Eric E. Easom
CHIEF EXECUTIVE
Eric E. Easom

COMPENSATION 2026

Salary$603,750
Stock Awards$164,133
Incentive Plan Pay$332,063
All Other Comp.$7,500
Total$1,382,985

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 25, 2022
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
21

PRICE TARGET

Target High$9.00
Target Low$9.00
Target Median$9.00
Target Consensus$9.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.—
NOV
5
THU

PRICE

$5.58 ▼ DOWN 2.79% (−$0.16)
$5.47$5.55$5.639:44 AM10:47 AM11:49 AM12:52 PM1:54 PM2:57 PM3:59 PM5.58

About AN2 Therapeutics, Inc.

https://www.an2therapeutics.com ↗

AN2 Therapeutics, Inc., a Menlo Park-based clinical-stage biopharmaceutical company founded in 2017, develops treatments for rare infectious diseases, including its oral drug epetraborole for chronic non-tuberculous mycobacterial lung disease.

INDUSTRY

Biotechnology

A PRODUCT AN2 THERAPEUTICS, INC. IS KNOWN FOR

AN2-502998
AN2-502998

AN2 Therapeutics' lead in development, AN2-502998, is a boron-based oral small molecule in Phase 1 trials targeting chronic Chagas disease, following the discontinuation of a previous lead asset.

COMPETITORS

COMPETITOR
INSM COMPARE
MNKD COMPARE
SPRO COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
51
LISTED HERE
12
RANKED BY POSITION SIZE
VTS.AX
0.00% · 853.0K
IWM
0.00% · 595.2K
GSSC
0.02% · 39.4K
DFAS
0.00% · 35.3K
XRS2.DE
0.00% · 24.2K
AVSC
0.00% · 20.2K
RSSL
0.01% · 12.6K
GERM
0.07% · 6.6K
SILX
0.27% · 6.2K
FSEG
0.09% · 1.2K
URTY
0.00% · 1.1K
RTYS.L
0.00% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
43.85%
HOLDERS
63
TOP 12 OF 63 · RANKED BY POSITION SIZE
Vivo Capital, LLC
3.2M sh · $10.79M
Commodore Capital LP
2.3M sh · $7.98M
Millennium Management LLC
2.2M sh · $7.6M
Almitas Capital LLC
1.5M sh · $5.06M
Vanguard Group Inc
1.1M sh · $1.37M
Adage Capital Partners Gp, L.L.C.
1.0M sh · $3.42M
Woodline Partners LP
993.7K sh · $3.4M
Boxer Capital Management, LLC
749.0K sh · $2.56M
Pfizer Inc
715.3K sh · $908.42K
Stonepine Capital Management, LLC
713.8K sh · $2.44M
Ameriprise Financial Inc
696.2K sh · $2.38M
Sio Capital Management, LLC
657.2K sh · $2.25M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
Trenor Cameron C. III
— · —
2026-08-24
★
DIRECTOR
Readnour Robin Shane
Sale · 16.7K shares
2026-08-17
★
DIRECTOR
Readnour Robin Shane
Sale · 18.7K shares
2026-08-17
★
DIRECTOR
Zakrzewski Joseph S
Sale · 405.9K shares
2026-08-14

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 1
1 GRADES IN THE LAST 12 MONTHS
Leerink Partners OUTPERFORM

SECTORS PEERS

PEERPRICE
QTTB$15.03COMPARE
SABS$3.79COMPARE
VRCA$5.69COMPARE
BOLD$2.83COMPARE
NXTC$6.09COMPARE
IBIO$1.36COMPARE
PLUR$1.53COMPARE
INTS$4.25COMPARE